Surufatinib
- Generic Name
- Surufatinib
- Drug Type
- Small Molecule
- Chemical Formula
- C24H28N6O3S
- CAS Number
- 1308672-74-3
- Unique Ingredient Identifier
- B2K5L1L8S9
- Background
Surufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).
- Indication
单药用于治疗无法手术切除的局部晚期或转移性、进展期非功能性、分化良好（G1、G2）的胰腺和非胰腺来源的神经内分泌瘤（pNETs）。
Savolitinib Plus TAGRISSO® Shows 56% Response Rate in MET-High Lung Cancer, HUTCHMED Reports
• SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in patients with EGFRm NSCLC with MET overexpression/amplification who progressed on first-line TAGRISSO®.
• Long-term survival benefits were observed in a Phase IIIb study of savolitinib in MET exon 14 skipping NSCLC, with treatment-naïve patients achieving a median overall survival of 28.3 months.
• The combination represents a promising chemotherapy-free oral treatment strategy to address resistance mechanisms in advanced NSCLC, with savolitinib and TAGRISSO® having received FDA Fast Track Designation in 2023.
Biomarker-Driven Clinical Trial Designs: Basket, Umbrella, and Platform Trials in Precision Medicine
• Basket trials leverage drug-target relationships to extend drug indications across different tumor types, identifying effective therapies based on shared molecular targets.
• Umbrella trials validate multiple therapies for a specific disease by comprehensively profiling molecular features, enabling personalized treatment strategies based on individual subtypes.
• Platform trials, as dynamic umbrella designs, efficiently screen optimal treatments in a long-term, adaptive model, ensuring patients receive the most effective interventions based on ongoing efficacy assessments.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath